全文获取类型
收费全文 | 44458篇 |
免费 | 5013篇 |
国内免费 | 58篇 |
专业分类
耳鼻咽喉 | 631篇 |
儿科学 | 1249篇 |
妇产科学 | 1258篇 |
基础医学 | 6919篇 |
口腔科学 | 1050篇 |
临床医学 | 6044篇 |
内科学 | 8237篇 |
皮肤病学 | 594篇 |
神经病学 | 3567篇 |
特种医学 | 1476篇 |
外国民族医学 | 1篇 |
外科学 | 6002篇 |
综合类 | 905篇 |
一般理论 | 29篇 |
预防医学 | 4575篇 |
眼科学 | 672篇 |
药学 | 3617篇 |
中国医学 | 59篇 |
肿瘤学 | 2644篇 |
出版年
2021年 | 543篇 |
2020年 | 406篇 |
2019年 | 700篇 |
2018年 | 801篇 |
2017年 | 577篇 |
2016年 | 717篇 |
2015年 | 753篇 |
2014年 | 1035篇 |
2013年 | 1576篇 |
2012年 | 2100篇 |
2011年 | 2164篇 |
2010年 | 1214篇 |
2009年 | 1083篇 |
2008年 | 1881篇 |
2007年 | 1954篇 |
2006年 | 1909篇 |
2005年 | 1868篇 |
2004年 | 1793篇 |
2003年 | 1735篇 |
2002年 | 1763篇 |
2001年 | 1558篇 |
2000年 | 1586篇 |
1999年 | 1355篇 |
1998年 | 561篇 |
1997年 | 459篇 |
1996年 | 393篇 |
1995年 | 465篇 |
1994年 | 440篇 |
1993年 | 405篇 |
1992年 | 1113篇 |
1991年 | 1049篇 |
1990年 | 1031篇 |
1989年 | 946篇 |
1988年 | 871篇 |
1987年 | 898篇 |
1986年 | 868篇 |
1985年 | 888篇 |
1984年 | 703篇 |
1983年 | 599篇 |
1982年 | 424篇 |
1981年 | 346篇 |
1980年 | 361篇 |
1979年 | 577篇 |
1978年 | 440篇 |
1977年 | 363篇 |
1976年 | 366篇 |
1974年 | 379篇 |
1973年 | 333篇 |
1972年 | 338篇 |
1971年 | 304篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Patrick Demkowicz BS Renelle Pointdujour-Lim MD Sofia Miguez BA Yesung Lee BS Bailey S. C. L. Jones BS Christopher A. Barker MD Marcus Bosenberg MD PhD David H. Abramson MD Alexander N. Shoushtari MD Harriet Kluger MD Jasmine H. Francis MD Mario Sznol MD Mathieu F. Bakhoum MD PhD 《Cancer》2023,129(20):3275-3286
2.
3.
4.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
5.
6.
7.
Gastro-oesophageal reflux disease (GORD) is symptomatic reflux of gastric contents into the oesophagus. Factors predisposing to GORD are loss of the physiological antireflux barrier and anatomic abnormalities of the oesophagus or diaphragm. Conservative measures and medical management results in resolution of symptoms in a majority of children. Surgery is indicated in the event of failure of medical management or severe complications. Surgical procedures include open or laparoscopic fundoplication in children with normal neurology; fundoplication with or without vagotomy and pyloroplasty; surgical feeding jejunostomy and oesophago-gastric dissociation in the severely neurologically impaired children. 相似文献
8.
Byung-Ho Yoon Lynne C. Jones Chung-Hwan Chen Edward Y. Cheng Quanjun Cui Wolf Drescher Wakaba Fukushima Valerie Gangji Stuart B. Goodman Yong-Chan Ha Philippe Hernigou Marc Hungerford Richard Iorio Woo-Lam Jo Vikas Khanduja Harry Kim Shin-Yoon Kim Tae-Young Kim Kyung-Hoi Koo 《The Journal of arthroplasty》2019,34(1):169-174.e1
Background
Although alcohol is a leading risk factor for osteonecrosis of the femoral head (ONFH) and its prevalence reportedly ranges from 20% to 45%, there are no unified classification criteria for this subpopulation. In 2015, Association Research Circulation Osseous decided to develop classification criteria for alcohol-associated ONFH.Methods
In June of 2017, Association Research Circulation Osseous formed a task force to conduct a Delphi survey. The task force invited 28 experts in osteonecrosis/bone circulation from 8 countries. Each round of the Delphi survey included questionnaires, analysis of replies, and feedback reports to the panel. After 3 rounds of the survey, consensus was reached on the classification criteria. The response rates for the 3 Delphi rounds were 100% (round 1), 96% (round 2), and 100% (round 3).Results
The consensus on the classification criteria of alcohol-associated ONFH included the following: (1) patients should have a history of alcohol intake >400 mL/wk (320 g/wk, any type of alcoholic beverage) of pure ethanol for more than 6 months; (2) ONFH should be diagnosed within 1 year after alcohol intake of this dose; and (3) patients should not have other risk factor(s).Conclusion
ARCO-established classification criteria to standardize clinical studies concerning AA-ONFH. 相似文献9.
10.
Benedict M Devereaux Andrew C F Taylor Eugene Athan David J Wallis Robyn R Brown Sue M Greig Fiona K Bailey Karen Vickery Elizabeth Wardle Dianne M Jones 《Journal of gastroenterology and hepatology》2019,34(12):2086-2089
Concern has been raised regarding the use of simethicone, a de‐foaming agent, during endoscopic procedures. Following reports of simethicone residue in endoscope channels despite high level disinfection, an endoscope manufacturer recommended that it not be used due to concerns of biofilm formation and a possible increased risk of microorganism transmission. However, a detailed mucosal assessment is essential in performing high‐standard endoscopic procedures. This is impaired by bubbles within the gastrointestinal lumen. The Gastroenterological Society of Australia's Infection Control in Endoscopy Guidelines (ICEG) Committee conducted a literature search utilizing the MEDLINE database. Further references were sourced from published paper bibliographies. Following a review of the available evidence, and drawing on extensive clinical experience, the multidisciplinary ICEG committee considered the risks and benefits of simethicone use in formulating four recommendations. Published reports have documented residual liquid or crystalline simethicone in endoscope channels after high level disinfection. There are no data confirming that simethicone can be cleared from channels by brushing. Multiple series report benefits of simethicone use during gastroscopy and colonoscopy in improving mucosal assessment, adenoma detection rate, and reducing procedure time. There are no published reports of adverse events related specifically to the use of simethicone, delivered either orally or via any endoscope channel. An assessment of the risks and benefits supports the continued use of simethicone during endoscopic procedures. Strict adherence to instrument reprocessing protocols is essential. 相似文献